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Abstract
The ethical dimensions of pharmacological cognitive enhancement have been widely discussed in academic circles and the
popular media, but missing from the conversation have been the perspectives of physicians - key decision makers in the
adoption of new technologies into medical practice. We queried primary care physicians in major urban centers in Canada
and the United States with the aim of understanding their attitudes towards cognitive enhancement. Our primary
hypothesis was that physicians would be more comfortable prescribing cognitive enhancers to older patients than to young
adults. Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the
regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant
adverse side effects. Respondents overwhelmingly reported increasing comfort with prescribing cognitive enhancers as the
patient age increased from 25 to 65. When asked about their comfort with prescribing extant drugs that might be
considered enhancements (sildenafil, modafinil, and methylphenidate) or our hypothetical cognitive enhancer to a normal,
healthy 40 year old, physicians were more comfortable prescribing sildenafil than any of the other three agents. When
queried as to the reasons they answered as they did, the most prominent concerns physicians expressed were issues of
safety that were not offset by the benefit afforded the individual, even in the face of explicit safety claims. Moreover, many
physicians indicated that they viewed safety claims with considerable skepticism. It has become routine for safety to be
raised and summarily dismissed as an issue in the debate over pharmacological cognitive enhancement; the observation
that physicians were so skeptical in the face of explicit safety claims suggests that such a conclusion may be premature.
Thus, physician attitudes suggest that greater weight be placed upon the balance between safety and benefit in
consideration of pharmacological cognitive enhancement.
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Introduction
Public acceptance of new technology ranges from wholehearted
embrace to outright rejection of radical technological change [1–
3]. Few advances bring this divergence of opinion into such stark
relief as the subject of cognitive enhancement in healthy persons,
in part because of the value society places upon cognitive ability
[4,5]. With technology increasingly permeating every corner of
modern life, it comes as no surprise that pharmacological
approaches which might ameliorate the normal cognitive decline
that accompanies aging and even enhance cognitive function in
young adults have garnered much interest.
To date, discussion regarding the propriety of pharmacological
cognitive enhancement has primarily been the domain of
bioethicists, philosophers, and scientists, with journalists and
enthusiastic consumers joining the fray at regular intervals [6–
27]. In contrast, the views of physicians on this subject have
received scant attention [28]. This is not to say that the subject of
the challenges that cognitive enhancement brings to the clinic has
gone unconsidered, but rather that the issue has been largely
restricted to thought leaders in academic medicine [10,18,29–31].
Given their roles as key decision makers in the adoption of new
technologies into medical practice, and moreover as individuals
likely to be called upon as the gatekeepers in dispensing
pharmaceutical cognitive enhancers, an examination of physician
attitudes on this topic struck us as overdue.
It may be instructive at the outset to draw attention to two
different conceptions of pharmacological cognitive enhancement.
The first recognizes that intellectual acuity declines as humans age,
even in the absence of frank disease. Distinct from the prodromic
cognitive decline that precedes dementia [32], the cognitive
decline that accompanies normal aging – formally termed age-
associated memory impairment or AAMI – is disturbing to many
[33]. The prevalence of AAMI, ranging from 38%–58% for
normal adults in their 609s [34,35], identifies the phenomenon as a
defining feature of normal aging, and situates AAMI at the
indistinct interface of normalcy and pathology. Moreover, because
the cognitive decline of AAMI is a decline, one can readily imagine
many to be sympathetic to the notion that in this instance,
pharmacological tools might constitute restoration.
The second conception is one that focuses much more directly
upon enhancing human traits, and is exemplified by discussions
regarding pharmacologically enhancing cognition in young adults
who exhibit no measurable cognitive decline. It is here that the full
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from enthusiasm and moral praiseworthiness through reasoned
skepticism and even overt antagonism [10,14,17,21,24,36,37].
Intuitions regarding the moral propriety of enhancement and
restoration are themes that recur, often implicitly but nearly
invariably, in discussions of cognitive enhancement in medical
practice.
Our primary objective was to examine physician views towards
prescribing pharmacological cognitive enhancers to cognitively
normal individuals. However, even asking the question raises a
larger issue of concern to many physicians: to what extent is it
appropriate to use modern medical technology to enhance the
healthy? In recent years, physicians have increasingly been asked
to prescribe drugs that fall in the ‘grey zone’ between treatment
and enhancement [27,38–40], but the process has been more
haphazard than deliberate: there has been no systematic program
by which the medical community has come together to decide
what avenues of treatment are appropriate. Rather, responsibility
for these important decisions has been left in the hands of the
pharmaceutical industry and the regulatory authorities; some have
suggested that the results have been less than ideal [27,38,41–43].
Thus, one objective of our study was to begin to provide an
opportunity for physicians, in particular general practitioners who
are most likely to be asked to prescribe such drugs in the future
[44], to express their attitudes towards enhancement in general,
and cognitive enhancement in particular.
Irrespective of whether physicians are explicitly aware of the
nosology of age-associated memory impairment, they are
implicitly aware of the fact that there exists a normal decline in
cognitive function in older individuals which is distinct from that
seen in dementia. Recognizing this, we reasoned that physicians
would feel that helping older patients overcome cognitive decline is
more akin to restoration than enhancement, and therefore is better
aligned with the proper goals of medicine than treating younger
patients who do not experience such decline and would be
perceived as pursuing enhancement rather than restoration. This
reasoning led us to our primary hypothesis that physicians would
be more comfortable prescribing cognitive enhancers to healthy
older patients than to healthy young adults. We also reasoned that
familiarity was an important consideration for physician prescrib-
ing behavior, and as a result hypothesized that physicians would
also feel more comfortable prescribing existing drugs that are
sometimes considered enhancers as compared to a hypothetical
drug specifically designed and marketed as a cognitive enhancer.
Here, we present data from over 200 physicians from across the
United States and Canada who responded to our survey.
Materials and Methods
Ethics Statement
The study was approved by the University of British Columbia
Behavioral Research Ethics Board (H09-00340).
We recruited primary care physicians practicing in major urban
centers in Canada and the United States by mailing out letters to
addresses in publicly available databases and by posting free
advertisements in medical association newsletters. Both the letter
and the newsletter ad highlighted the goals of the study and
directed interested participants to a web-based survey. The
incentive for participating was primarily to enable physicians
express their opinions on a conversation that had largely excluded
them, however, participants from each country also had the option
of entering into a random draw for their choice of an 8 GB Apple
iPod touchH,o ra$250 gift card to the bookstore of their choice
upon completion of the survey. The monetary incentive was
deliberately kept minimal in order to ensure that physicians had
sufficient interest in the research subject and thereby result in a
more robust data set.
The introductory paragraph of the survey briefly reviewed
normal age-related cognitive decline in healthy individuals and
introduced physicians to a hypothetical pharmaceutical agent that
had been approved by the regulatory authorities as a cognitive
enhancer for use in healthy adults, and was characterized as being
safe, effective, and without any significant adverse side effects. The
paragraph also reminded the physicians that the cognitive decline
associated with aging is not a disease, and that objective measures
of such normal cognitive decline can begin to appear as early as
the late 309s. Demographic data included respondents’ profes-
sional background, age, sex, ethnicity, place of birth, and primary
residence.
The survey began by probing physicians’ familiarity with
cognitive enhancement in healthy persons, and then progressed to
assess physician attitudes towards patients’ cognitive health. We
asked whether or not physicians probed cognitive function as a
part of routine physical exams in patients in three different age
groups; 25–40, 41–59, and 60 and older, and asked them to
indicate their reasons for probing cognitive health from lists we
provided. Next, we asked physicians to rate how comfortable they
felt prescribing the hypothetical cognitive enhancer to three
different patients: a 25-year-old, a 45-year-old, and a 65-year-old,
all of whom were otherwise healthy, but had come reporting
symptoms of age-related cognitive dysfunction. In order to assess
the impact of patients giving reasons for requesting the drug upon
physician attitudes, we again presented three patients: a 25-year-
old graduate student seeking to cope with the stress of graduate
school, a 45-year-old employee hoping to improve productivity,
and a 65-year-old individual feeling concerns about his ability to
perform everyday activities. Lastly, we probed physicians’ attitudes
towards prescribing our hypothetical cognitive enhancer and three
other pharmaceutical agents sometimes considered enhancers –
sildenafil, modafinil, and methylphenidate – in a 40-year-old
reporting symptoms consistent with the label indications for each
respective drug. We included modafinil and methylphenidate
because these agents are those that are most often mentioned in
the cognitive enhancement literature [7–25], and included
sildenafil because it satisfies the criteria for an enhancer but acts
on the body rather than the brain. Responses to all rating
questions were made on a 7-point Likert scale, with anchors at 1
(less comfortable) and 7 (more comfortable). The questions
provided the respondents with the opportunity to select the
reasons influencing their decisions, as well as the opportunity to
freely respond with comments.
Upon completing the survey, participants were given the
opportunity to leave their email addresses either to be re-contacted
for their willingness to participate in a future study, and/or to be
notified of the study results when it became available, and/or to
enter into the random prize draw. Respondents also had the
option not to select any of the options and simply submit the
survey. All respondents gave consent to participate, and to the use
of the data they provided.
The survey was hosted on the online survey tool Zoomerang,
and was kept open for a period of three months. Quantitative data
was analyzed using the GraphPad Prism 3.0 software (GraphPad
Software Inc., San Diego, CA, U.S.A). Student’s t-tests and one-
way ANOVAS were used to assess statistical significance in
differences between groups; data was considered statistically
significant when P values were less than or equal to 0.05. Content
analysis for the open-ended responses was manually performed
using the conceptual analysis method: coding was performed in an
Physicians Discuss Enhancers
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rather were developed during the coding process as new themes
were identified [45]. Concepts were coded based on the frequency
of occurrence, and themes with greater emphasis were identified
based on the number of times they appeared in the comments. To
determine inter-coder agreement, 15% of the open-ended
responses were randomly selected and assigned to a second coder
who was not involved with the initial coding process. Inter-coder
percent agreement was 95%, and Cohen’s Kappa coefficient (k)
was 0.54 (ReCal Software) [46].
Results
A total of 212 physicians responded to the survey (148 residing
and practicing in the USA, 64 residing and practicing in Canada);
88% were general practitioners. The demographic data for
respondents is shown in Table 1. Because some physicians were
recruited using advertisements placed in newsletters, we are unable
to provide corresponding demographic data on physicians in the
catchment areas, nor an accurate response rate. Using the data
from physicians who were contacted via letter in Vancouver and
Toronto as a guide, we estimate the response rate as ,4%. Thus,
the responding physicians should be viewed as comprising a
convenience sample of physicians rather than a representative sample.
Sixty one percent (61%) of respondents indicated that they had
read articles in either the popular press or the scientific literature
on the subject of cognitive enhancement within the last 5 years.
Four percent (4%) of respondents indicated they were ‘‘very
familiar’’ with the subject; 57% rated themselves as being ‘‘not
familiar’’ with the subject, while 39% indicated they were
‘‘somewhat familiar’’ with the subject.
Next, we probed physician attitudes to cognitive health in
patients in three different age groups: 25–40, 41–59, and 60 and
above. Eighty-four percent (84%) of physicians did not routinely
probe cognitive function in patients aged 25–40, and 65% of
physicians did not routinely probe cognitive function in patients
aged 41–59 (Figure S1); in both instances, the primary reason they
selected for not probing was that the patient was neither showing
nor complaining of cognitive deficits (Table S2). When asked to
freely respond, most physicians indicated that their practice was
‘‘treatment-focused’’ hence they didn’t probe cognitive function in
these age groups. However, by the time patients were aged 60 and
above, 79% of the physicians surveyed indicated that they
routinely probed cognitive function. The primary reason they
selected from the list we provided was age-appropriateness; most
physicians also indicated in their free response that they often
probed cognitive functions in this age group to assess for early
stages of memory loss.
The next set of questions directly addressed our primary
hypothesis that physicians would be more comfortable prescribing
cognitive enhancers to older patients than to young adults. We
queried how comfortable physicians would feel prescribing a
hypothetical cognitive enhancer to individuals who were 25, 45, or
65 years of age. Respondents overwhelmingly reported increasing
comfort with prescribing cognitive enhancers as the patient age
increased from 25 to 65, and the differences between age groups
were statistically significant (P,0.001; Figure 1). We performed
further stratified data analysis to assess whether or not physician
age, sex, or their self-reported familiarity with cognitive enhancers
correlated with their comfort with prescribing to patients in the 3
different age groups (Figure S3). We found no significant
differences between the groups based on physician age or
familiarity with cognitive enhancers; however, we did find that
while both male and female physicians were similarly uncomfort-
able with prescribing cognitive enhancers to the 25-year-old
patient, male physicians rated themselves as being significantly
more comfortable prescribing cognitive enhancers to both the 45-
and the 65-year-old patients.
We also assessed whether or not physicians would be swayed if
the patients gave reasons for requesting the cognitive enhancer
rather than simply reporting symptoms of cognitive dysfunction.
The same 3 patients as before were presented again, only now the
25-year-old was a graduate student who was looking to cope with
the stress of graduate school; the 45-year-old, a worker looking to
improve work productivity; and the 65 year old an older individual
having concerns about his ability to perform everyday activities.
The resultant data were not significantly different than their
responses without reasons (P.0.05).
The survey provided the respondents with a list of possible
reasons as to why they may have rated their comfort levels with
prescribing to patients in different age groups as they did. The
reasons and their responses are shown in Table 2.
While the predominant reasons for feeling uncomfortable
prescribing to the younger patient were a) that the patient did
not need the drug and b) fear of misuse, these sentiments were
markedly diminished in the case of the older patient, to whom
most physicians felt more comfortable prescribing in order to help
improve daily living and overall health and wellness.
Recognizing that the list of reasons we gave physicians may not
be exhaustive, we also provided the opportunity for additional
comments. In the free responses (Table S1), most physicians
expressed safety concerns about the drug even though we had
clearly indicated that the drug was safe, approved by regulatory
authorities, and devoid of significant side effects. Although safety
concerns remained predominant for all three patients, fewer
physicians expressed these concerns as the patient’s age increased
from 25 to 65 (37% to 28%). Rather, more physicians expressed
empathy and a desire to help the 65-year-old patient maintain a
good quality of life. Respondents also commented on the drug
being perceived as an unnecessary medical intervention, particu-
larly in the younger patient; concerns about enhancement falling
beyond the scope of medicine’s proper roles also emerged as
prevalent for scenarios involving patients in all age groups.
In order to assess how physicians feel about prescribing
cognitive enhancers in comparison with other drugs that are
already commonly prescribed but are sometimes considered
enhancers, we asked physicians to rate how comfortable they felt
prescribing any of the following: the hypothetical cognitive
enhancer, sildenafil, modafinil, and methylphenidate. In each
instance, the patient was a 40-year-old reporting symptoms
consistent with the label indications for the respective drug.
Physicians indicated they were significantly more comfortable
Table 1. Physician Demographic Data.
Specialty General Practitioners; 88%
Other; 12%
Sex Males; 55%
Females; 45%
Age 25–40; 36%41–59; 45%
60+;1 9 %
Number of years in practice 1–10; 45%
11–20; 24%
20+;3 1 %
The key demographic information collected from all survey participants.
doi:10.1371/journal.pone.0014322.t001
Physicians Discuss Enhancers
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14322Figure 1. Physicians’ Comfort Rating with Prescribing Cognitive Enhancers to Patients of Differing Ages. (A) Mean physician comfort
rating with prescribing the hypothetical cognitive enhancer to patients of differing ages. Physicians reported increasing comfort with prescribing
cognitive enhancers as the patient’s age increased from 25 to 65 (P,0.001). (B) Frequency of occurrence of each response on a 7-point Likert scale,
with anchors at 1 (less comfortable) and 7(more comfortable).
doi:10.1371/journal.pone.0014322.g001
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which they reported being quite uncomfortable prescribing
(Figure 2). As with prescribing cognitive enhancers to patients of
differing ages, we also found that male physicians rated themselves
as being significantly more comfortable than the females with
prescribing sildenafil, modafinil, and the hypothetical cognitive
enhancer to the 40-year-old patient (Figure S4).
To further assess physician angst about safety, as well as to
clarify why the majority of respondents were significantly more
comfortable prescribing sildenafil relative to the three other drugs,
we performed a brief follow-up survey specifically to address those
two issues. We queried all of the 66% of the initial survey
participants who had expressed their willingness to be re-contacted
for a future study, asking them how comfortable they were
prescribing the hypothetical cognitive enhancer to a 25-year-old,
this time encouraging them to specifically assume the availability
of favourable long-term safety data (Table S3). A subsequent
question shared our data from Figure 2 on sildenafil and the three
other drugs, and asked physicians to comment as to why they may
have responded as they did. The data revealed that the availability
of long-term safety data did indeed convince some physicians,
resulting in a statistically significant (P,0.001) increase in the
average comfort rating compared to the previously described 25
year old patients. Nonetheless, physicians remained clearly in the
uncomfortable range of the scale (mean =3.3) (Figure S2).
When asked to freely respond on their answer choices,
physicians’ overarching concerns remained safety issues that were
not necessarily offset by the benefits to the patient. A number of
Table 2. Reasons Affecting Physician Comfort with Prescribing Cognitive Enhancers to Patients of Different Ages.
Reasons 25 45 65
Fear of misuse 125 93 24
Patient does not need the drug 116 93 32
Availability of non-pharmacological methods of achieving the same goals 93 84 53
Undermines the values of personal effort 48 42 10
To improve patient’s overall health and wellness 38 69 134
Fear of legal liability 38 33 16
To help patient succeed 35 51 64
To improve daily living 25 74 146
It constitutes a form of cheating 26 13 3
Your cultural values 19 17 15
Respect for patient’s autonomy 15 34 60
Drug is age-appropriate 13 38 109
Patient’s socio-economic status 79 1 4
Your religious beliefs 41 3
Table 2 shows the total number of physicians who selected individual reasons from the list we offered as to why they rated their comfort levels as they did. Respondents
were able to select as many of the reasons as they felt was applicable.
doi:10.1371/journal.pone.0014322.t002
Figure 2. Physicians’ Comfort Rating with Prescribing Sildenafil, Methylphenidate, Modafinil, and a Hypothetical Cognitive
Enhancer. Physicians reported being significantly more comfortable prescribing sildenafil compared to the other 3 drugs (P,0.001); while
methylphenidate was rated significantly lower (P,0.01) when compared with sildenafil and the cognitive enhancer, but not modafinil.
doi:10.1371/journal.pone.0014322.g002
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enhancement in and of itself, raised concerns about fairness, and
also reiterated that they felt as though enhancement moves beyond
the proper goals of medicine.
When asked why they rated themselves as being more
comfortable with prescribing sildenafil than the three other drugs,
most physicians indicated an increased familiarity with the drug,
and a better safety profile (Table S4). Other concerns included the
abuse potential of stimulant drugs, the ability to objectively
measure the ‘‘success’’ of the drug, and the inclination to be more
cautious when prescribing any drug that affects brain function. In
their overall comments on their views on cognitive enhancement,
physicians continued to state safety worries as the primary issue of
concern (Table 3). The overall comments demonstrated that most
physicians were intensely risk-averse, and had a high distrust for
pharmaceuticals, particularly when the drug intervention is for
enhancement purposes.
The final question in the survey asked about physicians’
personal use of enhancers. Over 75% of the respondents stated
they routinely drank caffeinated products, with their primary
reasons being for mental alertness, and taste. When asked if they
would personally take a cognitive enhancer (of proven efficacy,
bearing regulatory approval, and devoid of significant side effects),
only 29% of the respondents answered with a definitive ‘‘no’’, 23%
of the respondents stated ‘‘yes,’’ while 48% stated ‘‘maybe.’’
Discussion
Our primary hypothesis was that physicians would feel more
comfortable prescribing cognitive enhancers to older patients than
to young adults, notwithstanding the fact that all of the patients
presented to them were normal, healthy adults. Physicians
overwhelmingly endorsed this view, reporting increasing comfort
as patient age increased from 25 to 65; this finding was similar
whether or not patients provided lifestyle reasons to support their
requests for the drug. When presented with a predefined checklist
which offered some possible reasons that physicians might offer in
support of their attitudes towards prescribing pharmacological
cognitive enhancers, physicians identified improvements in patient
quality of life as a major factor in motivating them to prescribe
these drugs to 65 year olds, while they characterized concerns
about misuse and the absence of a true need of the drug as staying
their hand in writing prescriptions to 25 year olds.
One reasonable interpretation of these data is that they reveal
differing attitudes towards enhancement as opposed to restoration:w h e n
considering younger adults, physicians viewed cognitive enhancers
as an unnecessary enhancement, but when evaluating older adults
who may be experiencing the normal cognitive decline associated
with aging, physicians viewed the treatment as restorative. Thus
physicians, whether through scholarship, implicit reasoning, or
other forms of knowledge, are generally attuned to the tensions that
accompany discussions of the treatment-enhancement distinction in
medical practice [38] The physicians in our data set generally
expressed sentiments which endorsed a relatively conservative view
of the enhancement debate: few physicians expressed enthusiasm
about the opportunity to use modern technology to produce
humans whose capabilities exceeded what is general considered
normal. Moreover, arguments grounded in physicians’ conception
of the proper role or purview of medical practice emerged as a
prevalentthemeinourcontentanalysisoffreeresponses.Whetherit
is the case that skepticism of the enterprise of enhancement drives
this view of medicine or vice versa is difficult to speculate; also
unclear is whether classifying cognitive enhancement as beyond
medicine’s scope prompts physicians to reconsider the status of
other,perhapsmorecommonlyaccepted,interventionsthatwemay
reasonably term enhancements.
An unexpected outcome of our study was the degree to which
physicians mistrust safety claims regarding pharmaceuticals. When
allowed to freely comment on their views on prescribing cognitive
enhancers, 49% of physicians who responded to this optional
question expressed safety concerns as dominating their rumination
on the topic. Most notable was the observation that these attitudes
persisted even though many of the physicians acknowledged that
they understood that the hypothetical cognitive enhancer was
approved by the regulatory authorities and had been described as
devoid of any significant side effects (for a sample of physician
comments, see supplementary data). So striking were these findings
that we carried out a follow-up survey to the subgroup of physicians
who agreed to be re-contacted, explicitly stating in the follow-up
question that respondents should assume that all safety concerns
have been put to rest by convincing long-term data. While this
further clarification increased the comfort level of physicians with
prescribing cognitive enhancers, the average comfort rating merely
went up from 2.3 to 3.3 on a scale of 1–7 (with the anchors of 1 and
7 indicating less and more comfort with prescribing, respectively),
indicating that even under these conditions physicians viewed even
data-backed safety claims as unconvincing.
The second hypothesis that we tested was that physicians would
feel more comfortable prescribing extant drugs that are sometimes
considered enhancers as compared to the hypothetical cognitive
enhancer presented in our scenario. When physician attitudes
towards prescribing sildenafil, modafinil, methylphenidate, or the
hypothetical cognitive enhancer to a healthy 40-year-old were
probed, the results indicated that the physicians were only
comfortable prescribing sildenafil, suggesting that the hypothetical
nature of our cognitive enhancer could not fully account for
physician concerns in the earlier part of the study.
We provided physicians with an opportunity to freely comment
on this finding in our follow-up study, asking them why they
thought they might have responded as they did. The primary
Table 3. Physician General Comments on Prescribing
Cognitive Enhancers.
Themes Percentage of Comments
Safety concerns 49%
Unnecessary medical intervention 15%
Lack of familiarity with subject 15%
Availability of Non-pharmacological Alternatives 12%
Efficacy concerns 9%
Empathy for patient/To help maintain quality of life 9%
Age-appropriateness 6%
Distributive Justice 5%
Treatment-focused physician 5%
Disease mongering 5%
Dependent on patient’s history 3%
Cost 3%
Respect for patient’s autonomy 2%
Coercion 1%
At the end of the survey, physicians received an optional comment box to
provide any additional views they may have about prescribing cognitive
enhancers. 59% of the total respondents left comments; these comments were
grouped into themes using the conceptual analysis method.
doi:10.1371/journal.pone.0014322.t003
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familiarity with sildenafil. This observation reinforces the overall
tenor of responses by physicians in the first part of this study,
namely that safety issues with drugs that are viewed as enhancers
dominate their list of concerns, and that these can only be
mitigated by the long-term success of the agent in daily practice.
Taken together, our data suggest that physicians are keenly
aware of the ethical landscape involved in prescribing cognitive
enhancers. Moreover, they appear to use this information in
appraising the tradeoff between safety and benefit when making
decisions about the propriety of prescribing such drugs for
enhancement as distinguished from restoration. At the same time,
physicians overwhelmingly utilized arguments from the perspec-
tive of safety to help them rationalize their decisions regarding
prescribing cognitive enhancers.
The issue of safety is often raised and summarily dismissed in
the debate over pharmacological cognitive enhancement by
deferring to the authority of regulatory approval [21] The
observation that physicians remained skeptical in the face of
explicit safety claims suggests that such a conclusion may be
premature. These data lend empirical force to the notion that
regulatory authorities would be well advised to maintain the
highest standards possible with respect to safety claims when
evaluating pharmaceutical agents that may be construed as being
enhancements. Finally, the findings of this study more generally
forewarn that as pharmacological cognitive enhancement moves
from discourse to reality, it will increasingly be important to move
the debate beyond academic analysis to include objective
engagement of individuals who are most likely to be affected.
Supporting Information
Figure S1 Physician Attitudes to Patients’ Cognitive Health.
Over 80% of physicians reported not routinely probing cognitive
function in patients aged 25-40, and 65% of physicians also did
not routinely probe cognitive function in patients’ aged 41-59.
However, 79% of the physicians surveyed routinely probe
cognitive function in patients’ aged 60 and above.
Found at: doi:10.1371/journal.pone.0014322.s001 (1.03 MB TIF)
Figure S2 Physicians’ Comfort Rating with Prescribing Cogni-
tive Enhancers to 25-year-old Patients in Different Scenarios.
Figure S2 compares how physicians rated their comfort levels with
prescribing the described cognitive enhancer to three 25-year-old
patients in 3 different scenarios: one who came in simply reporting
symptoms of cognitive dysfunction (no reason); the graduate
student (with reason); and the patient presented in the re-contact
survey, with all safety concerns presented as having been laid to
rest. The data revealed a significant increase (P,0.001) in comfort
rating after safety concerns were laid to rest, although the mean
rating was still 3.275.
Found at: doi:10.1371/journal.pone.0014322.s002 (1.14 MB TIF)
Figure S3 Stratified Analysis of Physicians’ Comfort Rating with
Prescribing Cognitive Enhancers to Patients. Mean physician
comfort rating with prescribing the hypothetical cognitive
enhancer to patients of differing ages stratified by physician age,
sex, and familiarity with cognitive enhancers. (A) There was no
significant difference between physicians in different age groups
(25–40; 41–59; 60+), P.0.05. (B) Male physicians were signifi-
cantly more comfortable with prescribing the cognitive enhancer
to 45- and 65-year-old patients (P,0.05) compared to the female
phyicians. (C) There was no significant difference (P.0.05) in
comfort level between physicians who rated themselves as being
‘‘familiar’’ or ‘‘unfamiliar’’ with cognitive enhancement in healthy
persons.
Found at: doi:10.1371/journal.pone.0014322.s003 (2.42 MB TIF)
Figure S4 Male and Female Physicians’ Comfort Rating with
Prescribing Sildenafil, Methylphenidate, Modafinil, and the
Cognitive Enhancer. Male physicians reported being significantly
more comfortable prescribing sildenafil (P,0.05); modafinil
(P,0.005); and the hypothetical cognitive enhancer (P,0.005),
when compared with female physicians.
Found at: doi:10.1371/journal.pone.0014322.s004 (1.16 MB TIF)
Table S1 Selected Comments on Physician Views on Prescrib-
ing Cognitive Enhancers.
Found at: doi:10.1371/journal.pone.0014322.s005 (0.03 MB
DOC)
Table S2 Physician Reasons for Probing or not Probing
Cognitive Health in Patients. Table S2 shows the percentage of
physicians that selected individual reasons from the list we offered
as to why they probe or do not probe cognitive health in patients
of different age groups during routine visits. Respondents were
able to select as many of the reasons as they felt was applicable.
Found at: doi:10.1371/journal.pone.0014322.s006 (0.04 MB
DOC)
Table S3 Comments on Prescribing Cognitive Enhancers to a
25-year-old, Assuming Long-term Favorable Safety Data. Physi-
cians were asked to freely respond on the question of prescribing
the hypothetical cognitive enhancer to a 25-year-old patient
assuming all the safety concerns they previously had have been
laid to rest with long-term convincing data. Their comments were
grouped into themes using the conceptual analysis method.
Found at: doi:10.1371/journal.pone.0014322.s007 (0.03 MB
DOC)
Table S4 Physician Comments on being more Comfortable
Prescribing Sildenafil Compared to the Other Three Drugs.
Physicians were asked to freely respond on why they feel the data
showed that the majority of the respondents were significantly
more comfortable prescribing sildenafil compared to the other 3
drugs. Their comments were grouped into themes using the
conceptual analysis method.
Found at: doi:10.1371/journal.pone.0014322.s008 (0.03 MB
DOC)
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